CARGO Therapeutics Future Growth
Future criteria checks 2/6
CARGO Therapeutics is forecast to grow earnings and revenue by 3.5% and 72.1% per annum respectively. EPS is expected to grow by 11.6% per annum. Return on equity is forecast to be -168.2% in 3 years.
Key information
3.5%
Earnings growth rate
11.6%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 72.1% |
| Future return on equity | -168.2% |
| Analyst coverage | Good |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 43 | -216 | -195 | -184 | 6 |
| 12/31/2025 | 1 | -213 | -214 | -189 | 7 |
| 12/31/2024 | N/A | -170 | -167 | -144 | 7 |
| 9/30/2024 | N/A | -154 | -142 | -134 | N/A |
| 6/30/2024 | N/A | -148 | -128 | -117 | N/A |
| 3/31/2024 | N/A | -121 | -107 | -97 | N/A |
| 12/31/2023 | N/A | -98 | -90 | -81 | N/A |
| 9/30/2023 | N/A | -80 | -71 | -64 | N/A |
| 6/30/2023 | N/A | -57 | -53 | -49 | N/A |
| 3/31/2023 | N/A | -46 | -42 | -39 | N/A |
| 12/31/2022 | N/A | -41 | -32 | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRGX's revenue (72.1% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: CRGX's revenue (72.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRGX is forecast to be unprofitable in 3 years.